Posters
Presenting Author Academic/Professional Position
Staff
Academic Level (Author 1)
Staff
Presentation Type
Poster
Discipline Track
Translational Science
Abstract Type
Program Abstract
Abstract
Purpose: Radiopharmaceutical (RP) theranostic represents a promising paradigm for personalized medicine and has been hailed by some as the future of cancer treatment.Following landmark clinical data showing improved patient outcomes, the subsequent approvals of Lutathera (177Lu-dotatate; Novartis) and Pluvicto (177Lu-vipivotide tetraxetan; Novartis) have illuminated the tremendous potential of radionuclide therapy in well-selected patients. Encouraged by these developments, we have developed a research-driven platform that provides the scientific vision and technical resources to discover, mature, and translate innovative radiopharmaceutical (RP) therapeutics and companion diagnostics on an industry-scale. Termed RADIATE, we believe that our broadly engaged end-to-end Therapeutics Discovery Research Platform enables us to collaborate with stakeholders, including those in vastly under-sourced communities to advance their research and promotes equity outreach to those communities of high health disparities.
Description: RADIATE (Radiopharmaceuticals for Advanced Diagnostic Imaging And ThErapy) is a comprehensive program, integrating basic, translational, and clinical research to deliver next-generation RP assets. The mission of RADIATE is: ‘to discover, translate, and leverage innovative radiopharmaceuticals to transform the care of patients with cancer’. The overarching goals of RADIATE ensure opportunities for impactful collaboration with industry, academic, and governmental partners. Our prioritized research programs include target prioritization, pharmacophore development, isotope production, radiochemistry, preclinical model development and evaluation, and translation to early-phase clinical trials.
Partners: Among the key strengths of the RADIATE program is our strategic alliance with leading field experts at MD Anderson and outside collaborators, including leaders in proteomics, data science (AI), leaders in well-established programs such as IACS and TRACTION, and front-line clinicians that help advance our RP discovery and development.
The MD Anderson core RADIATE infrastructure benefits from close affiliations with the Small Animal Imaging Facility and South Campus Human Research Imaging Facility, both in close proximity, thus positioning us with concept-to-clinic capabilities. (Figure 1)
Looking Ahead: Our vision for RADIATE is to drive breakthroughs in theranostics discovery, increase the value and impact of radionuclide therapy, and enhance patient reach, including those in communities of high health disparities. We offer an armamentarium of resources that will benefit prospective collaborators, especially those in disproportionately sourced communities, and to further advance the next-generation of RPs for transformative patient care.
Describes RADIATE resources
Recommended Citation
Ta, Robert; Manning, Henry Charles; and Graham, Brooke C., "MD Anderson RADIATE - An end-to-end research platform to drive radiopharmaceutical therapeutics discovery" (2025). Research Symposium. 135.
https://scholarworks.utrgv.edu/somrs/2025/posters/135
Included in
MD Anderson RADIATE - An end-to-end research platform to drive radiopharmaceutical therapeutics discovery
Purpose: Radiopharmaceutical (RP) theranostic represents a promising paradigm for personalized medicine and has been hailed by some as the future of cancer treatment.Following landmark clinical data showing improved patient outcomes, the subsequent approvals of Lutathera (177Lu-dotatate; Novartis) and Pluvicto (177Lu-vipivotide tetraxetan; Novartis) have illuminated the tremendous potential of radionuclide therapy in well-selected patients. Encouraged by these developments, we have developed a research-driven platform that provides the scientific vision and technical resources to discover, mature, and translate innovative radiopharmaceutical (RP) therapeutics and companion diagnostics on an industry-scale. Termed RADIATE, we believe that our broadly engaged end-to-end Therapeutics Discovery Research Platform enables us to collaborate with stakeholders, including those in vastly under-sourced communities to advance their research and promotes equity outreach to those communities of high health disparities.
Description: RADIATE (Radiopharmaceuticals for Advanced Diagnostic Imaging And ThErapy) is a comprehensive program, integrating basic, translational, and clinical research to deliver next-generation RP assets. The mission of RADIATE is: ‘to discover, translate, and leverage innovative radiopharmaceuticals to transform the care of patients with cancer’. The overarching goals of RADIATE ensure opportunities for impactful collaboration with industry, academic, and governmental partners. Our prioritized research programs include target prioritization, pharmacophore development, isotope production, radiochemistry, preclinical model development and evaluation, and translation to early-phase clinical trials.
Partners: Among the key strengths of the RADIATE program is our strategic alliance with leading field experts at MD Anderson and outside collaborators, including leaders in proteomics, data science (AI), leaders in well-established programs such as IACS and TRACTION, and front-line clinicians that help advance our RP discovery and development.
The MD Anderson core RADIATE infrastructure benefits from close affiliations with the Small Animal Imaging Facility and South Campus Human Research Imaging Facility, both in close proximity, thus positioning us with concept-to-clinic capabilities. (Figure 1)
Looking Ahead: Our vision for RADIATE is to drive breakthroughs in theranostics discovery, increase the value and impact of radionuclide therapy, and enhance patient reach, including those in communities of high health disparities. We offer an armamentarium of resources that will benefit prospective collaborators, especially those in disproportionately sourced communities, and to further advance the next-generation of RPs for transformative patient care.
